Barinthus Biotherapeutics/$BRNS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Barinthus Biotherapeutics
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
Ticker
$BRNS
Sector
Primary listing
Employees
105
Headquarters
Website
BRNS Metrics
BasicAdvanced
$29M
-
-$1.88
-0.66
-
Price and volume
Market cap
$29M
Beta
-0.66
52-week high
$2.92
52-week low
$0.64
Average daily volume
109K
Financial strength
Current ratio
8.037
Quick ratio
7.332
Long term debt to equity
11.297
Total debt to equity
13.682
Interest coverage (TTM)
-1,097.24%
Profitability
EBITDA (TTM)
-51.698
Effective tax rate (TTM)
0.15%
Management effectiveness
Return on assets (TTM)
-23.02%
Return on equity (TTM)
-62.25%
Valuation
Price to book
0.34
Price to tangible book (TTM)
0.41
Price to free cash flow (TTM)
-0.916
Free cash flow yield (TTM)
-109.18%
Free cash flow per share (TTM)
-0.767
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
26.25%
3-year earnings per share growth (CAGR)
83.17%
What the Analysts think about BRNS
Analyst ratings (Buy, Hold, Sell) for Barinthus Biotherapeutics stock.
BRNS Financial Performance
Revenues and expenses
BRNS Earnings Performance
Company profitability
BRNS News
AllArticlesVideos
BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
Business Wire·2 months ago
BRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Barinthus Biotherapeutics plc Is Fair to Shareholders
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Barinthus Biotherapeutics stock?
Barinthus Biotherapeutics (BRNS) has a market cap of $29M as of December 09, 2025.
What is the P/E ratio for Barinthus Biotherapeutics stock?
The price to earnings (P/E) ratio for Barinthus Biotherapeutics (BRNS) stock is 0 as of December 09, 2025.
Does Barinthus Biotherapeutics stock pay dividends?
No, Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders as of December 09, 2025.
When is the next Barinthus Biotherapeutics dividend payment date?
Barinthus Biotherapeutics (BRNS) stock does not pay dividends to its shareholders.
What is the beta indicator for Barinthus Biotherapeutics?
Barinthus Biotherapeutics (BRNS) has a beta rating of -0.66. This means that it has an inverse relation to market volatility.